A phase Ib/II clinical study of SGN-LIV1A administered in combination with atezolizumab as second-line therapy in patients with metastatic triple-negative breast cancer.
Phase of Trial: Phase I/II
Latest Information Update: 26 Jul 2017
At a glance
- Drugs Atezolizumab (Primary) ; SGN LIV1A (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Genentech
- 26 Jul 2017 New trial record
- 24 Jul 2017 According to a Seattle Genetics media release, Genentech will manage the study operations for this trial and Seattle Genetics will retain global development and commercialization rights to SGN-LIV1A.